Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Myotonic dystrophy: RNA pathogenesis comes into focus.

Laura P W Ranum1, John W Day

  • 1Institute of Human Genetics, University of Minnesota, Minneapolis, MN 55455, USA. ranum001@umn.edu

American Journal of Human Genetics
|April 6, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiac Safety Outcomes in Delandistrogene Moxeparvovec Clinical Trials for Duchenne Muscular Dystrophy with Up to 5 Years of Follow-up.

Cardiology and therapy·2026
Same author

Efficacy and safety of risdiplam in patients with type 1 spinal muscular atrophy: a 3-year open-label extension of the two-part, phase 2 FIREFISH trial.

The Lancet. Child & adolescent health·2026
Same author

Author Correction: High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial.

Nature medicine·2026
Same author

KIF5A downregulation in spinal muscular atrophy links axonal regeneration defects with ALS.

JCI insight·2026
Same author

PERK Deficiency Amplifies Molecular, Structural, and Network Vulnerability to Repetitive Mild Traumatic Brain Injury.

bioRxiv : the preprint server for biology·2026
Same author

An Antibody-Oligonucleotide Conjugate for Myotonic Dystrophy Type 1.

The New England journal of medicine·2026

Myotonic dystrophy (DM) involves genetic mutations causing multisystemic symptoms. Recent findings suggest a shared RNA gain-of-function mechanism underlies both DM1 and DM2, impacting cellular functions like gene splicing.

Area of Science:

  • Genetics and Molecular Biology
  • Neuromuscular Disorders

Background:

  • Myotonic dystrophy (DM) is a common adult muscular dystrophy affecting multiple organ systems.
  • DM presents with two main genetic forms: DM1 (chromosome 19) and DM2 (chromosome 3).
  • DM1 is caused by a CTG repeat expansion in the DMPK gene's 3' untranslated region.

Purpose of the Study:

  • To elucidate the pathogenic mechanisms underlying myotonic dystrophy types 1 and 2.
  • To discuss the clinical and molecular characteristics of DM1 and DM2.
  • To review animal and cell-based models developed for studying DM pathogenesis.

Main Methods:

  • Review of existing literature on DM1 and DM2 genetic mutations and pathogenesis.
  • Analysis of proposed RNA gain-of-function mechanisms involving CUG and CCUG repeats.

Related Experiment Videos

  • Examination of data from murine and cell-culture models of myotonic dystrophy.

    • Main Results:

    • Evidence suggests a common RNA gain-of-function mechanism for DM1 and DM2.
    • CUG and CCUG repeat expansions in untranslated regions disrupt cellular functions, including alternative splicing.
    • Pathogenic mechanisms for both DM types are increasingly understood through model systems.

    Conclusions:

    • Myotonic dystrophies (DM1 and DM2) share a common RNA-mediated pathogenic mechanism.
    • Repeat expansions in untranslated regions are key drivers of disease pathology.
    • Ongoing research utilizing various models continues to advance understanding of DM.